Genetically engineered mouse models (GEMMs) have been playing an essential role in expanding our knowledge about animal development, gene functions in vivo, and mechanisms of disease progression1,2. Germline GEMMs are traditionally developed in two ways. The first is the creation of transgenic mice by pronuclear injection of DNA plasmid followed by the transplantation of zygotes into pseudopregnant females. The other is the generation of knock-out/knock-in mice by homologous recombination in embryonic stem cells and the development of chimeras. Conditional knockout of genes in specific tissue or cell type of interest involves the breeding of genetically engineered alleles with Cre and flox sites for multiple generations. The whole process can be expensive and time-consuming, especially if the goal is to target multiple genes tissue-specifically. Recently, gene-editing technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) have been applied to several organs of the mice to induce tissue-specific genetic alterations for autochthonous cancer modeling3,4,5,6,7 or correct disease mutations in situ8,9. In these studies, the delivery of the gRNA vectors was usually achieved through adenoviral or lentiviral infection of the organ or hydrodynamic tail-vein injection. The relative ease of delivery of the CRISPR components to the lung and liver has greatly improved the convenience and efficiency of cancer modeling in these organs compared to the traditional Cre-Lox based mouse models.
The bladder urothelium is where most bladder tumors originate. The delivery of DNA vectors to the bladder urothelium for cancer modeling or gene therapy is hampered by a glycosaminoglycan layer on the apical urothelial surface, which acts as a barrier for adherence of infectious viruses10,11. Several pretreatment agents such as Syn3 and dodecyl-β-d-maltoside have been used to disrupt this barrier and enhance adenovirus infection efficiency12,13,14. Whether adeno-associated viruses (AAVs) can effectively infect the bladder has not been reported. Overall, a non-viral based delivery method would be desirable. Here, we describe a novel method developed in the lab for efficient DNA plasmid delivery to the mouse urothelium through urethra catheterization and electroporation. Because our approach does not involve chemical pretreatment of the glycosaminoglycan layer or virus production, it significantly simplifies the delivery of DNA plasmids into the mouse bladder urothelium, and should facilitate various in vivo studies of bladder diseases.